Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients
Source: View publication →
In patients with high-risk hypertension, the combination of the ACE inhibitor benazepril with the calcium channel blocker amlodipine was superior to the combination of benazepril with the diuretic hydrochlorothiazide in reducing major cardiovascular events.
Key Findings
Study Design
Study Limitations
Clinical Significance
The ACCOMPLISH trial challenged the long-standing guideline preference (e.g., JNC-7) for diuretic-based initial combination therapy in hypertension, demonstrating that an ACE inhibitor combined with a calcium channel blocker provides superior cardiovascular protection compared to an ACE inhibitor combined with a thiazide diuretic in high-risk patients.
Historical Context
At the time of publication, many hypertension guidelines recommended initial treatment with a diuretic based heavily on results from the ALLHAT trial. ACCOMPLISH provided pivotal evidence that the choice of second-line agent added to an ACE inhibitor significantly impacts cardiovascular outcomes, leading to a shift in clinical practice toward using RAS blockers with calcium channel blockers in high-risk hypertensive populations.
Guided Discussion
High-yield insights from every perspective
What is the physiological rationale for combining an ACE inhibitor with either a calcium channel blocker (CCB) or a thiazide diuretic in the management of hypertension, and how do these mechanisms provide synergy?
Key Response
Both combinations target different pathways of blood pressure regulation. ACE inhibitors block the renin-angiotensin-aldosterone system (RAAS), which promotes vasodilation and reduces sodium retention. Thiazides increase sodium excretion, which often triggers a compensatory rise in renin; adding an ACE inhibitor blunts this compensation. CCBs cause arterial vasodilation; combining them with an ACE inhibitor helps counteract the peripheral edema often caused by CCBs by promoting venous dilation through the RAAS blockade.
In a high-risk hypertensive patient with diabetes or established coronary artery disease, how does the ACCOMPLISH trial findings change your first-line choice of dual-combination therapy compared to the older ALLHAT-driven paradigm?
Key Response
The ALLHAT trial previously established chlorthalidone as a cornerstone of therapy. However, ACCOMPLISH specifically compared two combination therapies and found that benazepril/amlodipine was significantly superior to benazepril/HCTZ in reducing major cardiovascular events (20% relative risk reduction), despite similar blood pressure control. This suggests that for high-risk patients, the ACEi/CCB combination should be prioritized over the ACEi/Thiazide combination.
Considering the ACCOMPLISH trial's results on renal outcomes, how should these findings influence the management of patients with chronic kidney disease (CKD) who require multi-drug therapy?
Key Response
Secondary analyses of ACCOMPLISH demonstrated that the benazepril/amlodipine combination was more effective at slowing the progression of CKD (defined by doubling of serum creatinine or ESRD) than the benazepril/HCTZ combination. This challenges the historical preference for diuretics in CKD management and suggests that CCBs may offer superior nephroprotection when paired with RAAS inhibitors in non-edematous patients.
Given that blood pressure reduction was nearly identical in both arms of the ACCOMPLISH trial, what does this trial teach us about the 'pleiotropic' effects of antihypertensive classes and the concept of 'blood-pressure-independent' vascular protection?
Key Response
ACCOMPLISH is a landmark study because it decoupled blood pressure lowering from cardiovascular outcomes. Because the achieved BP was the same but the outcomes differed, it suggests that the amlodipine-based combination may provide superior endothelial protection, reduction in central aortic pressure, or better metabolic neutrality (less hyperglycemia or hypokalemia) compared to the HCTZ-based combination, highlighting that the 'choice' of agent is as critical as the 'target' BP.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The ACCOMPLISH trial was terminated early after an interim analysis by the Data and Safety Monitoring Board. How does early termination for efficacy impact the interpretation of the hazard ratios for the primary endpoint, and what are the statistical risks associated with this decision?
Key Response
Early termination for efficacy can lead to 'over-optimism' or an overestimation of the treatment effect size (hazard ratio). While the p-value was highly significant (p < 0.001), stopping early means the trial potentially captures a random high fluctuation in the benefit, and the confidence intervals might be narrower than if the trial had proceeded to its planned conclusion, necessitating caution when applying these exact effect sizes to cost-benefit models.
A critical reviewer might point out that ACCOMPLISH used hydrochlorothiazide (HCTZ) rather than chlorthalidone. How does the choice of the specific diuretic component affect the internal and external validity of the study’s comparison between the CCB and thiazide arms?
Key Response
HCTZ is shorter-acting and potentially less potent than chlorthalidone, which was the diuretic used in the ALLHAT trial. A reviewer would flag that the 'inferiority' of the diuretic arm in ACCOMPLISH might be a reflection of the specific drug (HCTZ) and its 24-hour BP profile rather than a class effect of thiazide-type diuretics, potentially limiting the generalizability of the results to patients on chlorthalidone or indapamide.
Based on the evidence from ACCOMPLISH, should clinical guidelines (such as ACC/AHA or ESC/ESH) transition from recommending 'any' two-drug combination for Stage 2 hypertension to specifically recommending ACEi/CCB as the preferred initial strategy in high-risk populations?
Key Response
Current ACC/AHA guidelines (2017) recommend both ACEi/CCB and ACEi/Diuretic as Class I, Level A options. However, the ACCOMPLISH data provides the most robust head-to-head evidence of superiority for the CCB combination in preventing CV events. The committee must weigh this against the lower cost and long-standing evidence for thiazides in stroke prevention, but for high-risk patients with CAD or diabetes, ACCOMPLISH provides a strong mandate to prioritize ACEi/CCB as the primary recommendation.
Clinical Landscape
Noteworthy Related Trials
ALLHAT Trial
Tested
Amlodipine, Lisinopril, or Chlorthalidone
Population
Patients aged 55+ with hypertension and at least one other CHD risk factor
Comparator
Chlorthalidone (primary reference)
Endpoint
Fatal CHD or nonfatal myocardial infarction
ASCOT-BPLA Trial
Tested
Amlodipine (+/- Perindopril) vs Atenolol (+/- Bendroflumethiazide)
Population
Hypertensive patients with at least three CV risk factors
Comparator
Atenolol-based regimen
Endpoint
Nonfatal myocardial infarction and fatal CHD
ONTARGET Trial
Tested
Telmisartan, Ramipril, or combination therapy
Population
Patients with vascular disease or high-risk diabetes
Comparator
Ramipril
Endpoint
Composite of cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis